COugh Among Hypertensive Patients Treated With Telmisartan, Who Had to Stop previoUs ACE-I Treatment Due to couGH in Poland
- Registration Number
- NCT01211171
- Lead Sponsor
- Bayer
- Brief Summary
In the light of ONTARGET and TRANSCEND studies results, it would be interesting to investigate the real-life telmisartan treatment tolerability. It is well known and accepted that the Real-life setting is much more adequate to reflect the antihypertensive and safety properties of the drug in comparison to the organized and scheduled setting of the clinical trial. Because there are not much data on the cough in relation to telmisartan, therefore it would we worth to observe the cough frequency and general treatment tolerance in patients treated with telmisartan, who had to stop their previous ACE-I treatment due to cough.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 2498
Inclusion Criteria
- hypertension
- age > 18
- ACE-I related cough
Read More
Exclusion Criteria
- Current treatment with telmisartan
- Cholestatic disorders and severe hepatic failure
- Allergy to telmisartan
- Pregnancy and lactation period
Read More
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Group 1 Telmisartan (Kinzal/Pritor, BAY68-9291) -
- Primary Outcome Measures
Name Time Method Cough frequency among telmisartan treated patients, who had to stop their previous ACE-I treatment due to cough 4 months after initiation
- Secondary Outcome Measures
Name Time Method General tolerability and safety of telmisartan treatment among patients, who had to stop their previous ACE-I treatment due to cough 4 months after initiation